Furthermore, we have demonstrated that CAF secretion of NRG-1 actively circumvents the inhibitory effect of erlotinib and promotes tumour growth providing an ‘escape’ mechanism to EGFR-targeted therapy. Here, NRG1 is linked to neoplasm.